NDLI: The future prospects of pharmacogenetics in oral anticoagulation therapy

Content Provider	PubMed Central
Author	Kamali, Farhad Pirmohamed, Munir
Copyright Year	2006
Abstract	Coumarins are the mainstay of oral anticoagulation for the treatment and prophylaxis of thromboembolic disorders. They have a narrow therapeutic index and regular monitoring is therefore required to avoid serious adverse effects. There is wide interindividual variability in dosage requirements, which makes anticoagulation response unpredictable. Current dosing titrations are haphazard and inconvenient and poor initial control leads to morbidity, and occasional mortality, because of bleeding and further thromboembolism. Recent discoveries have helped to characterize the factors that contribute to the interindividual variability in responses to coumarins. Patient and environmental factors that affect anticoagulation response to coumarins include age, body size, dietary vitamin K status, concurrent disease and drug interactions. More recently, single nucleotide polymorphisms in the 2C9 isoform of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKOR) have been shown to make significant contributions to the variability in coumarin dosage requirements. Polymorphisms in other genes that mediate the actions of coumarins may also contribute to this variability. Racial and cultural differences influence dosage requirements, which can be explained, at least in part, by genetic and dietary factors. Incorporation of genetic and environmental factors could help in the prediction of more individualized loading and maintenance doses for safer anticoagulation therapy.
Related Links	http://dx.doi.org/10.1111/j.1365-2125.2006.02679.x
Ending Page	751
Page Count	6
Starting Page	746
File Format	PDF
ISSN	03065251
e-ISSN	13652125
Journal	British Journal of Clinical Pharmacology
Issue Number	6
Volume Number	61
Language	English
Publisher	Blackwell Science Inc
Publisher Date	2006-06-01
Access Restriction	Open
Rights Holder	Blackwell Science Inc
Subject Keyword	Pharmacology (medical) Pharmacology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics

Pharmacogenetics and the future of medical practice

Delivery of Optimized Inpatient Anticoagulation Therapy: Consensus Statement from the Anticoagulation Forum

Reversal of Oral Anticoagulation

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

Challenges and future prospects of antibiotic therapy: from peptides to phages utilization

PHARMACOGENETICS OF INTRAVENOUS AND ORAL BUSULFAN IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

Antiplatelet and anticoagulation therapy

The Clinical Section of the British Pharmacological Society: prospects for the future

The future prospects of pharmacogenetics in oral anticoagulation therapy

Similar Documents

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics

Pharmacogenetics and the future of medical practice

Delivery of Optimized Inpatient Anticoagulation Therapy: Consensus Statement from the Anticoagulation Forum

Reversal of Oral Anticoagulation

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

Challenges and future prospects of antibiotic therapy: from peptides to phages utilization

PHARMACOGENETICS OF INTRAVENOUS AND ORAL BUSULFAN IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

Antiplatelet and anticoagulation therapy

The Clinical Section of the British Pharmacological Society: prospects for the future

The future prospects of pharmacogenetics in oral anticoagulation therapy